Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Homologous Recombination Deficiency”

94 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 94 results

Testing effectiveness (Phase 2)UnknownNCT04499118
What this trial is testing

AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer

Who this might be right for
HER2-negative Breast Cancer
Sichuan Provincial People's Hospital 100
Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Early research (Phase 1)Looking for participantsNCT06177171
What this trial is testing

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Who this might be right for
BRCA1 MutationBRCA2 MutationBRCA Mutation+3 more
Pamela Munster 18
Not applicableStudy completedNCT03159572
What this trial is testing

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 996
Large-scale testing (Phase 3)Ended earlyNCT00448266
What this trial is testing

Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 12
Early research (Phase 1)Looking for participantsNCT06856499
What this trial is testing

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Who this might be right for
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver 50
Testing effectiveness (Phase 2)WithdrawnNCT03032614
What this trial is testing

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Who this might be right for
Breast Cancer Stage IVOvarian CancerBRCA1 Mutation+1 more
The University of Texas Health Science Center at San Antonio
Testing effectiveness (Phase 2)WithdrawnNCT06365970
What this trial is testing

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Who this might be right for
MMR-D/MSI-H Colorectal Cancers
Ibrahim Halil Sahin
Testing effectiveness (Phase 2)Study completedNCT04240106
What this trial is testing

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)

Who this might be right for
Breast CancerBreast Cancer Metastatic
MedSIR 14
Not applicableNot Yet RecruitingNCT06242392
What this trial is testing

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Fujian Cancer Hospital 250
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06419179
What this trial is testing

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

Who this might be right for
Small Cell Lung Carcinoma
University of Cologne 29
Testing effectiveness (Phase 2)Looking for participantsNCT04515836
What this trial is testing

Olaparib in Patients With HRD Malignant Mesothelioma

Who this might be right for
MesotheliomaHomologous Recombination Deficiency
University of Chicago 56
Testing effectiveness (Phase 2)Study completedNCT01982448
What this trial is testing

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Dana-Farber Cancer Institute 147
Testing effectiveness (Phase 2)Ended earlyNCT05126433
What this trial is testing

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorUrothelial Cancer+2 more
Jazz Pharmaceuticals 47
Not applicableUnknownNCT05310370
What this trial is testing

HRD and Resistance to PAPPi in EOC Patients

Who this might be right for
Epithelial Ovarian CancerHomologous Recombination DeficiencyHomologous Recombination Repair Gene Mutation+4 more
Lei Li 400
Early research (Phase 1)Looking for participantsNCT04890613
What this trial is testing

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Who this might be right for
Advanced Solid Tumor
Senhwa Biosciences, Inc. 52
Testing effectiveness (Phase 2)Ended earlyNCT03712930
What this trial is testing

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Homologous Recombination Deficiency (HRD)
BeiGene 13
Not applicableStudy completedNCT04991051
What this trial is testing

Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube Cancer
AstraZeneca 605
Early research (Phase 1)Active Not RecruitingNCT00777582
What this trial is testing

Phase I Comparative Bioavailability Study

Who this might be right for
Solid Tumors
AstraZeneca 197
Testing effectiveness (Phase 2)UnknownNCT05732129
What this trial is testing

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Who this might be right for
Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
Fudan University 29
Load More Results